SCHEMBL5648087

SCHEMBL5648087

CNS(=O)(=O)c1sc2c(ccc(=O)n2-c2ccccc2)c1-c1ccccc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.33
ALDH1A1 P00352 4/20 0.33
GAA P10253 4/20 0.32
KDM4E B2RXH2 1/20 0.32
LMNA P02545 2/20 0.32
MAT2A P31153 1/20 0.32
CA12 O43570 2/20 0.31
CA1 P00915 2/20 0.31
CA2 P00918 2/20 0.31
CA5A P35218 2/20 0.31
CA9 Q16790 2/20 0.31
CA5B Q9Y2D0 2/20 0.31
MAPT P10636 1/20 0.31
MAPK8 P45983 1/20 0.31
MAPK9 P45984 1/20 0.31
TGM2 P21980 2/20 0.31
PKM P14618 1/20 0.30
HKDC1 Q2TB90 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
GSK3A P49840 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651010 0.84 KMT2A (0.35) KMT2AALDH1A1GAALMNAPKM
SCHEMBL5648185 0.78 MAT2A (0.38) KMT2AALDH1A1GAAKDM4ELMNA
SCHEMBL5652629 0.76 PLK1 (0.41) KMT2AALDH1A1KDM4ELMNAMAPT
SCHEMBL5654089 0.75 KMT2A (0.38) KMT2AALDH1A1GAAKDM4ELMNA
SCHEMBL5652117 0.73 CYP1A2 (0.41) KMT2AALDH1A1GAAKDM4ELMNA
SCHEMBL5652751 0.73 LMNA (0.34) KMT2AALDH1A1GAAKDM4ELMNA
SCHEMBL5650705 0.73 KMT2A (0.43) KMT2AALDH1A1KDM4ELMNAMAPT
SCHEMBL5650652 0.72 ADORA3 (0.38) KMT2AALDH1A1GAAKDM4ELMNA
SCHEMBL5649920 0.72 KMT2A (0.40) KMT2AALDH1A1GAAKDM4ELMNA
SCHEMBL5649021 0.72 KMT2A (0.39) KMT2AALDH1A1KDM4ELMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 KMT2A 1815/4885ALDH1A1 1498/4885GAA 4108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.